Cargando…

A novel cuproptosis-related immune checkpoint gene signature identification and experimental validation in hepatocellular carcinoma

Copper-induced death, also termed cuproptosis, is a novel form of programmed cell death and is promising as a new strategy for cancer therapeutics. Elevated copper levels in tumor cells are positively associated with high PD-L1 expression. Nonetheless, the prognostic significance of cuproptosis-rela...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Yusai, Zhang, Wei, Sun, Jia, Sun, Lingyan, Meng, Fanjie, Yu, Huiying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630496/
https://www.ncbi.nlm.nih.gov/pubmed/36323801
http://dx.doi.org/10.1038/s41598-022-22962-y
_version_ 1784823615226642432
author Xie, Yusai
Zhang, Wei
Sun, Jia
Sun, Lingyan
Meng, Fanjie
Yu, Huiying
author_facet Xie, Yusai
Zhang, Wei
Sun, Jia
Sun, Lingyan
Meng, Fanjie
Yu, Huiying
author_sort Xie, Yusai
collection PubMed
description Copper-induced death, also termed cuproptosis, is a novel form of programmed cell death and is promising as a new strategy for cancer therapeutics. Elevated copper levels in tumor cells are positively associated with high PD-L1 expression. Nonetheless, the prognostic significance of cuproptosis-related immune checkpoint genes (CRICGs) in hepatocellular carcinoma remains to be further clarified. This study aimed to construct the prognostic CRICG signature to predict the immunotherapy response and outcomes of HCC patients. The co-expressed CRICGs were first screened through Pearson correlation analysis. Based on the least absolute shrinkage and selection operator-COX regression analyses, we identified a prognostic 5-CRICGs model, which closely correlates with poor outcomes, cancer development, and immune response to hepatocellular carcinoma. External validation was conducted using the GSE14520 dataset. Lastly, qRT-PCR was performed to determine the expression of the CRICGs in HCC. In summary, we developed and validated a novel prognostic CRICG model based on 5 CRICGs. This prognostic signature could effectively forecast the outcomes and immune response of HCC patients, which may serve as biomarkers for anticancer therapy.
format Online
Article
Text
id pubmed-9630496
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-96304962022-11-04 A novel cuproptosis-related immune checkpoint gene signature identification and experimental validation in hepatocellular carcinoma Xie, Yusai Zhang, Wei Sun, Jia Sun, Lingyan Meng, Fanjie Yu, Huiying Sci Rep Article Copper-induced death, also termed cuproptosis, is a novel form of programmed cell death and is promising as a new strategy for cancer therapeutics. Elevated copper levels in tumor cells are positively associated with high PD-L1 expression. Nonetheless, the prognostic significance of cuproptosis-related immune checkpoint genes (CRICGs) in hepatocellular carcinoma remains to be further clarified. This study aimed to construct the prognostic CRICG signature to predict the immunotherapy response and outcomes of HCC patients. The co-expressed CRICGs were first screened through Pearson correlation analysis. Based on the least absolute shrinkage and selection operator-COX regression analyses, we identified a prognostic 5-CRICGs model, which closely correlates with poor outcomes, cancer development, and immune response to hepatocellular carcinoma. External validation was conducted using the GSE14520 dataset. Lastly, qRT-PCR was performed to determine the expression of the CRICGs in HCC. In summary, we developed and validated a novel prognostic CRICG model based on 5 CRICGs. This prognostic signature could effectively forecast the outcomes and immune response of HCC patients, which may serve as biomarkers for anticancer therapy. Nature Publishing Group UK 2022-11-02 /pmc/articles/PMC9630496/ /pubmed/36323801 http://dx.doi.org/10.1038/s41598-022-22962-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Xie, Yusai
Zhang, Wei
Sun, Jia
Sun, Lingyan
Meng, Fanjie
Yu, Huiying
A novel cuproptosis-related immune checkpoint gene signature identification and experimental validation in hepatocellular carcinoma
title A novel cuproptosis-related immune checkpoint gene signature identification and experimental validation in hepatocellular carcinoma
title_full A novel cuproptosis-related immune checkpoint gene signature identification and experimental validation in hepatocellular carcinoma
title_fullStr A novel cuproptosis-related immune checkpoint gene signature identification and experimental validation in hepatocellular carcinoma
title_full_unstemmed A novel cuproptosis-related immune checkpoint gene signature identification and experimental validation in hepatocellular carcinoma
title_short A novel cuproptosis-related immune checkpoint gene signature identification and experimental validation in hepatocellular carcinoma
title_sort novel cuproptosis-related immune checkpoint gene signature identification and experimental validation in hepatocellular carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630496/
https://www.ncbi.nlm.nih.gov/pubmed/36323801
http://dx.doi.org/10.1038/s41598-022-22962-y
work_keys_str_mv AT xieyusai anovelcuproptosisrelatedimmunecheckpointgenesignatureidentificationandexperimentalvalidationinhepatocellularcarcinoma
AT zhangwei anovelcuproptosisrelatedimmunecheckpointgenesignatureidentificationandexperimentalvalidationinhepatocellularcarcinoma
AT sunjia anovelcuproptosisrelatedimmunecheckpointgenesignatureidentificationandexperimentalvalidationinhepatocellularcarcinoma
AT sunlingyan anovelcuproptosisrelatedimmunecheckpointgenesignatureidentificationandexperimentalvalidationinhepatocellularcarcinoma
AT mengfanjie anovelcuproptosisrelatedimmunecheckpointgenesignatureidentificationandexperimentalvalidationinhepatocellularcarcinoma
AT yuhuiying anovelcuproptosisrelatedimmunecheckpointgenesignatureidentificationandexperimentalvalidationinhepatocellularcarcinoma
AT xieyusai novelcuproptosisrelatedimmunecheckpointgenesignatureidentificationandexperimentalvalidationinhepatocellularcarcinoma
AT zhangwei novelcuproptosisrelatedimmunecheckpointgenesignatureidentificationandexperimentalvalidationinhepatocellularcarcinoma
AT sunjia novelcuproptosisrelatedimmunecheckpointgenesignatureidentificationandexperimentalvalidationinhepatocellularcarcinoma
AT sunlingyan novelcuproptosisrelatedimmunecheckpointgenesignatureidentificationandexperimentalvalidationinhepatocellularcarcinoma
AT mengfanjie novelcuproptosisrelatedimmunecheckpointgenesignatureidentificationandexperimentalvalidationinhepatocellularcarcinoma
AT yuhuiying novelcuproptosisrelatedimmunecheckpointgenesignatureidentificationandexperimentalvalidationinhepatocellularcarcinoma